Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

Trends in Cancer

Volumn 2, Issue 1, 2016, Pages 49-63

  Lipinski, Kamil A ^a   Barber, Louise J ^a   Davies, Matthew N ^a   Ashenden, Matthew ^a   Sottoriva, Andrea ^a   Gerlinger, Marco ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

cancer evolution; cancer genetics; drug resistance; precision cancer medicine; predictive biomarkers; prognostic biomarkers

Indexed keywords

CANCER GENETICS; CANCER PATIENT; CANCER RESEARCH; DRUG SELECTIVITY; GENETIC DRIFT; HUMAN; MALIGNANT NEOPLASM; MUTATION RATE; PERSONALIZED MEDICINE; POPULATION GENETICS; POPULATION SIZE; PREDICTION; PRIORITY JOURNAL; REVIEW; STOCHASTIC MODEL;

EID: 85009088974     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2015.11.003     Document Type: Review

References (107)

1. 1 Stratton, M.R., et al. The cancer genome. Nature 458 (2009), 719–724.
2. 2 Meyerson, M., et al. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11 (2010), 685–696.
3. 3 Reuter, J.A., et al. High-throughput sequencing technologies. Mol. Cell 58 (2015), 586–597.
4. 4 Dienstmann, R., et al. Genomic medicine frontier in human solid tumors: prospects and challenges. J. Clin. Oncol. 31 (2013), 1874–1884.
5. 5 Gnant, M., Steger, G.G., Fighting overtreatment in adjuvant breast cancer therapy. Lancet 374 (2009), 2029–2030.
6. 6 Nowell, P.C., The clonal evolution of tumor cell populations. Science 194 (1976), 23–28.
7. 7 Anderson, K., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469 (2011), 356–361.
8. 8 Diaz, L.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 (2012), 537–540.
9. 9 Gerlinger, M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
10. 10 Awad, M.M., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368 (2013), 2395–2401.
11. 11 Gerlinger, M., et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46 (2014), 225–233.
12. 12 Bettegowda, C., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med., 6, 2014, 224ra24.
13. 13 Gundem, G., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520 (2015), 353–357.
14. 14 Sprouffske, K., et al. Cancer in light of experimental evolution. Curr. Biol. 22 (2012), R762–R771.
15. 15 Lynch, M., The Origins of Genome Architecture. 2007, Sinauer Associates.
16. 16 Szendro, I.G., et al. Predictability of evolution depends nonmonotonically on population size. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 571–576.
17. 17 Blount, Z.D., et al. Historical contingency and the evolution of a key innovation in an experimental population of Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 7899–7906.
18. 18 Roberts, S.A., Gordenin, D.A., Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14 (2014), 786–800.
19. 19 Alexandrov, L.B., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
20. 20 Nik-Zainal, S., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149 (2012), 979–993.
21. 21 Stamatoyannopoulos, J.A., et al. Human mutation rate associated with DNA replication timing. Nat. Genet. 41 (2009), 393–395.
22. 22 Schuster-Bockler, B., Lehner, B., Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature 488 (2012), 504–507.
23. 23 Gisselsson, D., et al. Generation of trisomies in cancer cells by multipolar mitosis and incomplete cytokinesis. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 20489–20493.
24. 24 Stephens, P.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144 (2011), 27–40.
25. 25 Nathanson, D.A., et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343 (2014), 72–76.
26. 26 de Bruin, E.C., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346 (2014), 251–256.
27. 27 Wang, Y., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512 (2014), 155–160.
28. 28 Dewhurst, S.M., et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4 (2014), 175–185.
29. 29 Garsed, D.W., et al. The architecture and evolution of cancer neochromosomes. Cancer Cell 26 (2014), 653–667.
30. 30 Shlien, A., et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 47 (2015), 257–262.
31. 31 Henderson, S., et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7 (2014), 1833–1841.
32. 32 Levy, S.F., et al. Quantitative evolutionary dynamics using high-resolution lineage tracking. Nature 519 (2015), 181–186.
33. 33 Vermeulen, L., et al. Defining stem cell dynamics in models of intestinal tumor initiation. Science 342 (2013), 995–998.
34. 34 Kozar, S., et al. Continuous clonal labeling reveals small numbers of functional stem cells in intestinal crypts and adenomas. Cell Stem Cell 13 (2013), 626–633.
35. 35 Bhang, H.E., et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21 (2015), 440–448.
36. 36 Jain, K., Krug, J., Deterministic and stochastic regimes of asexual evolution on rugged fitness landscapes. Genetics 175 (2007), 1275–1288.
37. 37 Nik-Zainal, S., et al. The life history of 21 breast cancers. Cell 149 (2012), 994–1007.
38. 38 Landau, D.A., et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26 (2014), 813–825.
39. 39 Yates, L.R., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21 (2015), 751–759.
40. 40 Sottoriva, A., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 4009–4014.
41. 41 Gulati, S., et al. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur. Urol. 66 (2014), 936–948.
42. 42 Gerrish, P.J., Lenski, R.E., The fate of competing beneficial mutations in an asexual population. Genetica 102–103 (1998), 127–144.
43. 43 Zhang, J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346 (2014), 256–259.
44. 44 Korona, R., et al. Evidence for multiple adaptive peaks from populations of bacteria evolving in a structured habitat. Proc. Natl. Acad. Sci. U.S.A. 91 (1994), 9037–9041.
45. 45 Cortot, A.B., Janne, P.A., Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur. Respir. Rev. 23 (2014), 356–366.
46. 46 Yu, H.A., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19 (2013), 2240–2247.
47. 47 Sequist, L.V., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1700–1709.
48. 48 Piotrowska, Z., et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5 (2015), 713–722.
49. 49 Niederst, M.J., et al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21 (2015), 3924–3933.
50. 50 Shi, H., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4 (2014), 80–93.
51. 51 Juric, D., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518 (2015), 240–244.
52. 52 Patch, A.M., et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521 (2015), 489–494.
53. 53 Piotrowska, Z., et al. Variation in mechanisms of acquired resistance among EGFR-mutant NSCLC patients with more than 1 postresistant biopsy. Int. J. Radiat. Oncol., 90, 2014, 2.
54. 54 Das Thakur, M., et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494 (2013), 251–255.
55. 55 Siravegna, G., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21 (2015), 795–801.
56. 56 Sniegowski, P.D., Gerrish, P.J., Beneficial mutations and the dynamics of adaptation in asexual populations. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 365 (2010), 1255–1263.
57. 57 Holyoake, T., et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94 (1999), 2056–2064.
58. 58 Greaves, M., Cancer stem cells as ‘units of selection’. Evol. Appl. 6 (2013), 102–108.
59. 59 Shah, N.P., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002), 117–125.
60. 60 Khorashad, J.S., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J. Clin. Oncol. 26 (2008), 4806–4813.
61. 61 Gobbi, P.G., et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J. Clin. Oncol. 19 (2001), 1388–1394.
62. 62 Park, J.H., et al. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. Clin. Lung Cancer 14 (2013), 383–389.
63. 63 Waclaw, B., et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 525 (2015), 261–264.
64. 64 Gerlinger, M., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 369 (2013), 1172–1173.
65. 65 Rooney, M.S., et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
66. 66 McFarland, C.D., et al. Impact of deleterious passenger mutations on cancer progression. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 2910–2915.
67. 67 Lang, G.I., et al. Pervasive genetic hitchhiking and clonal interference in forty evolving yeast populations. Nature 500 (2013), 571–574.
68. 68 Gerlinger, M., et al. Cancer: evolution within a lifetime. Annu. Rev. Genet. 48 (2014), 215–236.
69. 69 Ellegren, H., Microsatellites: simple sequences with complex evolution. Nat. Rev. Genet. 5 (2004), 435–445.
70. 70 Birkbak, N.J., et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 71 (2011), 3447–3452.
71. 71 Swanton, C., et al. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5 (2015), 704–712.
72. 72 Goldie, J.H., Coldman, A.J., The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 44 (1984), 3643–3653.
73. 73 Bozic, I., et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife, 2, 2013, e00747.
74. 74 Tol, J., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360 (2009), 563–572.
75. 75 Sottoriva, A., et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47 (2015), 209–216.
76. 76 Reiter, J.G., et al. The effect of one additional driver mutation on tumor progression. Evol. Appl. 6 (2013), 34–45.
77. 77 Barber, L.J., et al. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr. Opin. Genet. Dev. 30C (2014), 1–6.
78. 78 Graeber, T.G., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996), 88–91.
79. 79 Heindl, A., et al. Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. Lab. Invest. 95 (2015), 377–384.
80. 80 Haffner, M.C., et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123 (2013), 4918–4922.
81. 81 Yachida, S., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 (2010), 1114–1117.
82. 82 Letouze, E., et al. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol., 11, 2010, R76.
83. 83 Basanta, D., Anderson, A.R., Exploiting ecological principles to better understand cancer progression and treatment. Interface Focus, 3, 2013, 20130020.
84. 84 Nourmohammad, A., et al. Universality and predictability in molecular quantitative genetics. Curr. Opin. Genet. Dev. 23 (2013), 684–693.
85. 85 Mustonen, V., Lässig, M., From fitness landscapes to seascapes: non-equilibrium dynamics of selection and adaptation. Trends Genet. 25 (2009), 111–119.
86. 86 Su, K-Y., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30 (2012), 433–440.
87. 87 Laurent-Puig, P., et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 21 (2015), 1087–1097.
88. 88 Landau, D.A., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152 (2013), 714–726.
89. 89 Bozic, I., Nowak, M.A., Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 15964–15968.
90. 90 Newman, A.M., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20 (2014), 548–554.
91. 91 Carreira, S., et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med., 6, 2014, 254ra125.
92. 92 Humphries, A., et al. Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), E2490–E2499.
93. 93 Sottoriva, A., et al. Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. Cancer Res. 73 (2013), 41–49.
94. 94 de Visser, J.A., Krug, J., Empirical fitness landscapes and the predictability of evolution. Nat. Rev. Genet. 15 (2014), 480–490.
95. 95 Misale, S., et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4 (2014), 1269–1280.
96. 96 Awad, M.M., Shaw, A.T., ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol. 12 (2014), 429–439.
97. 97 Misale, S., et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med., 6, 2014, 224ra226.
98. 98 Garnett, M.J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483 (2012), 570–575.
99. 99 Wilson, F.H., et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27 (2015), 397–408.
100. 100 Chen, S., et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160 (2015), 1246–1260.
101. 101 Eirew, P., et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518 (2015), 422–426.
102. 102 van de Wetering, M., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (2015), 933–945.
103. 103 Tenaillon, O., et al. The molecular diversity of adaptive convergence. Science 335 (2012), 457–461.
104. 104 Ortmann, C.A., et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 372 (2015), 601–612.
105. 105 Schenk, M.F., et al. Quantifying the adaptive potential of an antibiotic resistance enzyme. PLoS Genet., 8, 2012, e1002783.
106. 106 Reiter, J.G., et al. TTP: tool for tumor progression. Sharygina, N., Veith, H., (eds.) Computer Aided Verification, LNCS, 8044, 2013, Springer, 101–106.
107. 9 still really fit one gram of tumor tissue?. Cell Cycle 8 (2009), 505–506.